Aptamer Sciences Inc. (291650)

Overview

Aptamer Sciences, Inc. is a pioneering bio venture enterprise specializing in aptamer technology, established in 2011. With its headquarters located in Seongnam, South Korea, the company is dedicated to leveraging its aptamer technology platform to innovate in the fields of therapeutics and diagnostics. This technology platform encompasses the discovery, optimization, and development processes required to bring new aptamer-based solutions to market. Through its focused approach, Aptamer Sciences is aiming to address some of the most pressing challenges in medical science today.

Products and Services

• AlloMAp Platform Program for Therapeutics:

  The AlloMAp platform represents Aptamer Sciences, Inc.'s dedication to the therapeutic applications of aptamer technology. This platform is designed to discover and develop novel aptamer-based therapeutics, aiming to provide innovative treatments for various medical conditions.

• BiFAp Platform Program for Therapeutics:

  Similar to AlloMAp, the BiFAp platform is tailored towards the development of therapeutic solutions but focuses on a different spectrum of diseases or conditions. Through BiFAp, Aptamer Sciences seeks to expand its therapeutic offerings, leveraging the specificity and adaptability of aptamers.

• Diagnostic Kits for Lung and Pancreatic Cancer:

  Understanding the critical importance of early detection in cancer treatment, Aptamer Sciences, Inc. has developed diagnostic kits for lung and pancreatic cancer. These kits are designed to facilitate early diagnosis, enhancing treatment outcomes and survival rates for these daunting diseases.

• In-vitro Diagnostic Kits for Early Diagnosis of Lung Cancer:

  The company also offers in-vitro diagnostic kits specifically targeted at the early diagnosis of lung cancer. By focusing on this early detection phase, Aptamer Sciences aims to make a significant impact on the management and treatment of lung cancer, improving patient prognosis and quality of life.